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Background
A spectrum of viral vaccines, including the annual 620
million doses of trivalent influenza vaccines, are being
produced in embryonated eggs of pharmaceutical qual-
ity, or with primary cells derived from such eggs [1,2].
Regulatory guidelines and experience for these processes
are established and proven against time for 75 years [1].
However, production with galline primary material is
not optimal and producers sometimes struggle to pro-
vide needed vaccine doses. Among the challenges are
limitations in supply [3] and that rigid intervalls between
husbandry, harvest of eggs and inoculation with vaccine
seed must be accomodated [4]. Manipulation of embryo-
nated eggs and disposal of solid biohazardous waste that
accumulates if vaccines are being produced in egg cav-
ities come at considerable costs [5,6]. Finally, risk of
contamination with environmental and endogenous
agents is high [7-9].
Such issues can be circumvented if a continuous cell
line is used to propagate viral vaccines [1]. Master Cell
Banks can be prepared in sufficient amounts and tested
for presence of adventitious agents ahead of production,
chemically defined media obviate dependence on animal
derived components, and predictable seed trains towards
a wide range of bioreactor volumes allow flexible and
fast response times for vaccine production [10].
However, there is a regulatory concern that DNA
derived from the immortal production substrate may be
transferred to vaccine recipients [1]. Risk calculations
that relate values for the length of typical oncogenes,
number of such genes in the genome and fragmentation
of DNA during purification have arrived at a permissive
threshold of 10 ng of nucleic acid per vaccine dose [1].
Materials and methods
We investigated purification of modified vaccinia virus
Ankara (MVA) produced on the continuous avian cell
line CR.pIX. MVA is a versatile and highly immuno-
genic viral vector, but also known to pose unique chal-
lenges in production processes [11]. For example, the
majority of the infectious units of MVA remain cell-
associated so that downstream purification must initiate
with a complete lysate of the infected cultures (rather
than cell-free supernatant). The viral particles are
furthermore too large for conventional filtration, centri-
fugation and chromatographic separation. Finally,
because MVA cannot amplify in human recipients, a
desired safety feature, each vaccine dose requires 108
infectious units for full efficacy. This dose is 400-fold
above that recommended for replication-competent pox-
viruses and necessitates efficient and robust manufacturing
processes [10].
Derivation and properties of the anatine CR.pIX cell
line have been described previously [12], as well as cell-
associated propagation of poxviruses in suspension cul-
tures in chemically-defined media by induction of CR.
pIX aggregates [10]. We used GFP-recombinant versions
of both genetically stable strains of MVA, wildtype and
strain MVA-CR that was isolated previously with help
of the suspension process [13].
Purification of MVA was performed with CIM mono-
lithic chromatography columns from Bia Separations
[14]. The CIM monoliths consist of a single piece of
highly porous material with a network of branched
channels. These channels can be provided with large 6
µm-diameters and can be functionalized with various
ion exchange groups.
Results
Different monolith chemistries from cation and anion
exchange to hydrophobic interaction were screened.
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However, host cell-derived DNA was difficult to deplete in
these and other experiments. We suspected a strong asso-
ciation of viral envelopes and nucleic acids so that cellular
DNA will always be copurified with the infectious units.
Various chaotropic reagents were investigated to disrupt,
preferrably to even prevent formation of these complexes
[15]. Prevention of complex formation is an option
because integrity of CR.pIX cells is maintained during
MVA replication. The time for release of nuclear DNA in
presence or absence of chaotropes during manufacturing
can therefore be determined by the timing of sonication of
the infected cultures (Figure 1 (a)).
A representative chromatogram obtained with a col-
umn at 1 mL scale is shown in Figure 1 (b). The load was
adjusted to a conductivity of less than 10 mS/cm prior to
application on the column. Washing was performed with
100 mM NaCl, elution by increasing the concentration of
NaCl to conductivities of up to 150 mS/cm. Quantifica-
tion of relative changes in DNA levels [16] by qPCR
against the viral genome and an abundant cellular pseu-
dogene demonstrated a strong enrichment of viral DNA
only in presence of chaotropes (Figure 1 (c)). Without
chaotropes the ratio of viral to cellular DNA remains
close to that of the load. In subsequent experiments we
measured an excess of 65 × for MVA (108 infectious
units is 1-fold vaccine dose) and 130 × for the admissable
DNA load (1-fold corresponds to 10 ng) in the product
fraction (Figure 1 (d)).
Conclusions
To replace eggs with a continuous avian cell line as vaccine
production substrate is desirable but requires reduction of
Figure 1 Prevention of copurification of host-cell derived DNA. (a) Enveloped virions appear to associate stably with host cell DNA.
Chaotropes were added prior to lysis to prevent complex formation and to allow DNase to access its substrate without sterical hindrance. (b) A
representative chromatogram of a large pore CIM ion exchange column loaded with lysate of MVA-infected CR.pIX cells. Elution fraction A is
designed to remove DNA, the infectious units collect in B. (c) Quantification of the ratios of viral to cellular DNA by qPCR. The ratios of the load
were set to 1. Blue columns show values obtained in presence and green in absence of chaotropes. (d) Quantification of yields relative to
vaccine dose for a process with chaotropes.
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host cell DNA levels to less than 10 ng per vaccine dose.
We used chaotropes to interfere with the association of cel-
lular DNA and infectious units. This step, together with
chromatography, yields a product fraction that is only
2-fold away from the admissable DNA load per efficaceous
infectious activity. Next optimization steps will focus on
improved processing of the lysate for additional depletion
of cellular DNA.
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